

## DAFTAR PUSTAKA

- Alkady, M., & Ibrahim, I. (2019). Role of Asymmetric Dimethylarginine and Nitric Oxide in Type 2 Diabetes Mellitus and Its Cardiovascular Complications. *Egyptian Journal of Radiation Sciences and Applications*, 0(0), 0–0. <https://doi.org/10.21608/ejrsa.2019.13784.1074>
- Ando, R., Ueda, S., Yamagishi, S., Miyazaki, H., Kaida, Y., Kaifu, K., Yokoro, M., Nakayama, Y., Obara, N., Fukami, K., Takeuchi, M., & Okuda, S. (2013). Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. *Diabetes and Vascular Disease Research*, 10(5), 436–441. <https://doi.org/10.1177/1479164113486662>
- Banjarnahor, S., & Damayanti, R. (2023). The Role of ADMA in Various Diseases. *Cermin Dunia Kedokteran*, 50, 227–233.
- Cai, W., Torreggiani, M., Zhu, L., Chen, X., He, J. C., Striker, G. E., & Vlassara, H. (2010). AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC- $\delta$ : implications for vascular disease. *American Journal of Physiology-Cell Physiology*, 298(3), C624–C634. <https://doi.org/10.1152/ajpcell.00463.2009>
- Chang, J.-B., Chu, N.-F., Syu, J.-T., Hsieh, A.-T., & Hung, Y.-R. (2011). Advanced glycation end products (AGEs) in relation to atherosclerotic lipid profiles in middle-aged and elderly diabetic patients. *Lipids in Health and Disease*, 10(1), 228. <https://doi.org/10.1186/1476-511X-10-228>
- Decroli, E. (2019). *Diabetes Mellitus Tipe 2* (A. Kam, Y. P. Effendi, G. P. Decroli, & A. Rahmadi, Eds.; Pertama). Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas.
- Di Pino, A., Currenti, W., Urbano, F., Scicali, R., Piro, S., Purrello, F., & Rabuazzo, A. M. (2017). High intake of dietary advanced glycation end-products is associated with increased arterial stiffness and inflammation in subjects with type 2 diabetes. *Nutrition, Metabolism and Cardiovascular Diseases*, 27(11), 978–984. <https://doi.org/10.1016/j.numecd.2017.06.014>
- Direktorat Pengendalian Penyakit Tidak Menular, D. J. P. P. M. dan P. L. K. K. R. (2015). *Pedoman Umum Pengendalian Obesitas*.
- Eliana, F., Suwondo, P., Makmun, L. H., & Harbuwono, D. S. (2009). Faktor risiko disfungsi endotel pada prediabetes. *Jurnal Kedokteran Yarsi*, 17(3), 160–168.
- ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, J., Lyons, S. K., Perry, M. Lou, Prahalad, P., Pratley, R. E., Zabbay, R. A. (2023). Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2023. *Diabetes Care*, 46(Supplement\_1), S19–S97. <https://doi.org/10.2337/dc23-S002>
- Li, Z., Yao, Q., Chen, F., Liu, H., Zhang, Z., & Lin, J. (2021). Wnt/ $\beta$ -catenin signaling promotes gastric cancer cell migration and invasion via Wnt/ $\beta$ -catenin



- signaling pathway. *Clinical and Translational Oncology*, 23(2), 325–334. <https://doi.org/10.1007/s12094-020-02422-7>
- Guo, X., Jin, W., & Xing, Y. (2024). Levels of asymmetric dimethylarginine in plasma and aqueous humor: a key risk factor for the severity of fibrovascular proliferation in proliferative diabetic retinopathy. *Frontiers in Endocrinology*, 15. <https://doi.org/10.3389/fendo.2024.1364609>
- Hariawan, K. N., & Suastika, K. (2008). Hubungan Kendali Glikemik dengan Asymmetric Dimethylarginine Penderita Diabetes Melitus Tipe 2 Lanjut Usia. *Jurnal Penyakit Dalam*, 9(3), 203–214.
- Hirai, T., Fujiyoshi, K., Yamada, S., Matsumoto, T., Kikuchi, J., Ishida, K., Ishida, M., Yamaoka-Tojo, M., Inomata, T., Shigeta, K., & Tojo, T. (2022). Advanced Glycation End Products Are Associated with Diabetes Status and Physical Functions in Patients with Cardiovascular Disease. *Nutrients*, 14(15), 3032. <https://doi.org/10.3390/nu14153032>
- Hsu, C.-P., Hsu, P.-F., Chung, M.-Y., Lin, S.-J., & Lu, T.-M. (2014). Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2 diabetes: relation with the glycemic control. *Cardiovascular Diabetology*, 13(1), 156. <https://doi.org/10.1186/s12933-014-0156-1>
- International Diabetes Federation. (2021). *IDF Diabetes Atlas 10th edition*. [www.diabetesatlas.org](http://www.diabetesatlas.org)
- Karabulut, A., Sahin, T., & Sahin, M. (2023). Neopterin and asymmetric dimethylarginine levels in patients with type 2 diabetic retinopathy. *Journal of Clinical Trials and Experimental Investigation*, 2(2), 66–73. <https://doi.org/10.5281/zenodo.8011560>
- Kasper, D. L., Fauci, A. S., Hauser, S. L., & Longo, D. L. (2016). Diabetes Mellitus. In *Harrison's Manual of Medicine*, 19e. McGraw-Hill Education. [accessmedicine.mhmedical.com/content.aspx?aid=1137770110](http://accessmedicine.mhmedical.com/content.aspx?aid=1137770110)
- Kementerian Kesehatan Republik Indonesia. (2019). *Laporan Nasional Riskesdas 2018*. Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan.
- Kopytek, M., Ząbczyk, M., Mazur, P., Undas, A., & Natorka, J. (2020). Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes. *Cardiovascular Diabetology*, 19(1), 92. <https://doi.org/10.1186/s12933-020-01068-7>
- Lee, W., Lee, H. J., Jang, H. B., Kim, H.-J., Ban, H.-J., Kim, K. Y., Nam, M. S., Choi, J. S., Lee, K.-T., Cho, S. B., Park, S. I., & Lee, H.-J. (2018). Asymmetric dimethylarginine (ADMA) is identified as a potential biomarker of insulin resistance in skeletal muscle. *Scientific Reports*, 8(1), 2133. <https://doi.org/10.1038/s41598-018-20549-0>
- X. (2019). Advanced glycation end products and adipocytokines stress in placental tissues of pregnant women with gestational diabetes mellitus. *Experimental and Therapeutic Medicine*. <https://doi.org/10.3892/etm.2019.7623>
- Wang, W., He, K., Ma, H., Ma, B., Zhao, P., & Tian, L. (2019). Correlation between Serum Asymmetric Dimethylarginine Level and



- Microvascular Complications in Diabetes Mellitus: A Meta-Analysis. *BioMed Research International*, 2019, 1–8. <https://doi.org/10.1155/2019/2941861>
- Mardia, I. K., Syafril, S., & Sazli, B. I. (2024). *Hubungan antara Asymmetric Dimethylarginine (ADMA) dan Ankle-Brachial Index (ABI) dengan Tingkat Keparahan Ulkus Kaki Diabetes* [Universitas Sumatera Utara]. <https://repositori.usu.ac.id/handle/123456789/100297>
- Mayer, O., Gelžinský, J., Seidlerová, J., Mateřánková, M., Mareš, Š., Svobodová, V., Trefil, L., Cífková, R., & Filipovský, J. (2021). The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker? *Journal of Human Hypertension*, 35(3), 240–249. <https://doi.org/10.1038/s41371-020-0327-3>
- Mulyati, S. (2016). Peranan Advanced Glycation End-products pada Diabetes. *Cermin Dunia Kedokteran*, 43(6), 422–426.
- MyBioSource. (2021a). *Human Advanced Glycation End Products (AGEs) ELISA Kit Catalog Number: MBS267540*. MyBioSource. <https://www.mybiosource.com/human-elisa-kits/advanced-glycation-end-products-ages/267540>
- MyBioSource. (2021b). *Human Asymmetric dimethylarginine (ADMA) ELISA Kit*. MyBioSource. <https://www.mybiosource.com/human-elisa-kits/asymmetric-dimethylarginine-adma/264847>
- Perkumpulan Endokrinologi Indonesia. (2021). *Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia*.
- Rezaei, M., Rabizadeh, S., Mirahmad, M., Hajmiri, M. S., Nakhjavani, M., Hemmatabadi, M., & Shirzad, N. (2022). The association between advanced glycation end products (AGEs) and ABC (hemoglobin A1C, blood pressure, and low-density lipoprotein cholesterol) control parameters among patients with type 2 diabetes mellitus. *Diabetology & Metabolic Syndrome*, 14(1), 122. <https://doi.org/10.1186/s13098-022-00895-w>
- Sakin, A. (2021). The Evaluation of the Relationship Between Albuminuria and Serum Asymmetric Dimethyl Arginine Level in Type-2 Diabetes Mellitus. *Eurasian Journal of Medical Investigation*. <https://doi.org/10.14744/ejmi.2021.18888>
- Sergi, D., Boulestin, H., Campbell, F. M., & Williams, L. M. (2021). The Role of Dietary Advanced Glycation End Products in Metabolic Dysfunction. *Molecular Nutrition & Food Research*, 65(1). <https://doi.org/10.1002/mnfr.201900934>
- Siervo, M., & Bluck, L. J. C. (2012). In vivo nitric oxide synthesis, insulin sensitivity, and asymmetric dimethylarginine in obese subjects without and with metabolic syndrome. *Metabolism*, 61(5), 680–688. <https://doi.org/10.1016/j.metabol.2011.10.003>



a, R. K., Graf, E. E., Schmölder, I., Upson, B. M., Kapoor, O.,  
low, M. R., Wascher, T. C., Pachinger, O., & Cooke, J. P. (2003).  
sfunction Induced by Hyperhomocyst(e)inemia. *Circulation*,  
3. <https://doi.org/10.1161/01.CIR.0000085067.55901.89>

Yepuri, G., & Ghebremariam, Y. T. (2015). Endothelium-Derived  
s an Antiatherogenic Mechanism: Implications for Therapy.

- Methodist DeBakey Cardiovascular Journal*, 11(3), 166.  
<https://doi.org/10.14797/mdcj-11-3-166>
- Tahara, N., Yamagishi, S., Matsui, T., Takeuchi, M., Nitta, Y., Kodama, N., Mizoguchi, M., & Imaizumi, T. (2012). Serum Levels of Advanced Glycation End Products (AGEs) are Independent Correlates of Insulin Resistance in Nondiabetic Subjects. *Cardiovascular Therapeutics*, 30(1), 42–48.  
<https://doi.org/10.1111/j.1755-5922.2010.00177.x>
- Uribarri, J., Cai, W., Ramdas, M., Goodman, S., Pyzik, R., Chen, X., Zhu, L., Striker, G. E., & Vlassara, H. (2011). Restriction of Advanced Glycation End Products Improves Insulin Resistance in Human Type 2 Diabetes. *Diabetes Care*, 34(7), 1610–1616. <https://doi.org/10.2337/dc11-0091>
- Vazzana, N., Ranalli, P., Cuccurullo, C., & Davì, G. (2012). Diabetes mellitus and thrombosis. *Thrombosis Research*, 129(3), 371–377.  
<https://doi.org/10.1016/j.thromres.2011.11.052>
- Wisudawati, N. E., Rita, C., Lismayanti, L., & Sugianli, A. K. (2018). Differences Of Asymmetric Dimethyl Arginine Level In Patients With Diabetic Nephropathy And Non-Diabetic Nephropathy. *Indonesian Journal of Clinical Pathology and Medical Laboratory*, 24(3), 262–265. <https://doi.org/10.24293/ijcpml.v24i3.1420>
- Yaşar, H., Şenol, M. G., Kendirli, T., Önem, Y., Özdağ, F., & Saraçoğlu, M. (2011). Serum asymmetric dimethylarginine levels in diabetic patients with neuropathy. *Diabetes Research and Clinical Practice*, 92(2), 223–227.  
<https://doi.org/10.1016/j.diabres.2011.01.015>
- Zaciragic, A., Dervisevic, A., Avdagic, N., Babic, N., Valjevac, A., Lepara, O., & Huskic, J. (2022). The impact of type 2 diabetes duration on serum asymmetric dimethylarginine and C-reactive protein concentration in Bosnian patients. *Endocrine Regulations*, 56(4), 271–278. <https://doi.org/10.2478/enr-2022-0029>

